Breaking News Instant updates and real-time market news.

CATB

Catabasis Pharmaceuticals

$5.79

-0.37 (-6.01%)

08:05
10/04/16
10/04
08:05
10/04/16
08:05

Catabasis reaches target enrollment for Part B of MoveDMD trial

Catabasis Pharmaceuticals announced that target enrollment of 30 patients has been reached for Part B of the MoveDMD trial, a 12-week trial to assess the safety and efficacy of edasalonexent, CAT-1004, in Duchenne muscular dystrophy. Edasalonexent is an oral small molecule that the Company believes has the potential to be a disease-modifying therapy for DMD patients, regardless of their underlying dystrophin mutation. Catabasis has previously reported positive safety, tolerability, pharmacokinetics and biomarker results from Part A of the trial. Based on scheduling of the enrolled patients as of September 30, 2016, the Company expects to report top-line safety and efficacy results from this Phase 2 trial in the first half of Q1 2017. In the first portion of the MoveDMD trial (Part A), 17 ambulatory boys between ages 4 and 7 with a genetically confirmed diagnosis of DMD across a range of dystrophin mutations received edasalonexent. The boys were steroid naive or had not used steroids for at least six months prior to the trial. This portion of the trial was conducted at three sites in the U.S., and assessed the safety, tolerability and pharmacokinetics of edasalonexent in patients at three dosing levels during seven days of dosing. Sixteen of the boys who participated in the first part of the MoveDMD trial are participating in Part B. Phase 2 of the MoveDMD trial is a randomized, double-blind, placebo-controlled trial of approximately 30 boys to evaluate the safety and efficacy of edasalonexent in DMD over a 12-week period at five clinical trial sites in the U.S. at two dosing levels, 67 mg/kg/day and 100 mg/kg/day. The open-label extension was initiated in July and includes dosing with edasalonexent for 36 weeks beyond the 12-week placebo-controlled portion of the trial and will evaluate longer term safety and efficacy with the same clinical end points. PPMD and the Muscular Dystrophy Association are providing funding to support participant travel for the MoveDMD trial.

CATB Catabasis Pharmaceuticals
$5.79

-0.37 (-6.01%)

12/10/15
WEDB
12/10/15
NO CHANGE
Target $27
WEDB
Outperform
Catabasis results could lead to partnership discussions, says Wedbush
Wedbush analyst Liana Moussatos said Catabsis announced the initiation of its Phase 2a trial of CAT-2054, its orally available SREBP inhibitor, in patients with hypercholesterolemia. Moussatos believes results from this trial could provide a basis for partnering discussions with a Big Pharma company with a presence in the metabolic space. The analyst sees potential peak worldwide sales of over $5.7B, and a partnering deal could have a lucrative upfront payment as well as significant milestones and royalties. Moussatos rates Catabasis an Outperform with a $27 price target on shares.
04/08/16
SBSH
04/08/16
NO CHANGE
SBSH
Citi lays out potential targets after break of Pfizer, Allergan deal
Citi analysts Yigal Nochomovitz, Liav Abraham and Joel Beatty argue that the break of the Pfizer (PFE), Allergan (AGN) merger could accelerate smaller scale acquisitions in the Biotechnology sector. The implication that larger companies could accelerate M&A activity to bolster pipelines in lieu of the mega-merger pathway aided shares in the sector this week, the analysts contend in a research note. They now believe that Ardelyx (ARDX), Medivation (MDVN), Ophthotech (OPHT), Puma Biotechnology (PBYI), Portola Pharmaceuticals (PTLA), Ultragenyx (RARE), Relypsa (RLYP) and Versartis (VSAR) have a greater probability of being acquired in the next 12-18 months. Beside these favored names for a takeover, analyst Joel Beatty sees a greater chance of Catabasis Pharmaceuticals (CATB), Intercept Pharmaceuticals (ICPT), Novavax (NVAX) and Raptor Pharmaceuticals (RPTP) getting acquired over the next 18 months.
06/08/16
COWN
06/08/16
NO CHANGE
Target $30
COWN
Outperform
Catabasis Pharmaceuticals DMD drug potential undervalued, says Cowen
Cowen noted Catabasis Pharmaceuticals halted its Phase-2 trial for CAT-2054 as it did not meet its primary endpoint in reducing LDL in hypercholesterolemia. Cowen, however, feels the shares are undervalued based on the potential of its edasalonexent drug candidate for Duchenne muscular dystropy, or DMD. The firm said the drug has the potential to be effective in all DMD patients regardless of the patient's underlying dystrophin mutation. Cowen maintained its Outperform rating and $30 price target on Catabasis shares.
06/09/16
SBSH
06/09/16
NO CHANGE
Target $8
SBSH
Buy
Catabasis Pharmaceuticals price target lowered to $8 from $16 at Citi
Citi analyst Joel Beatty halved his price target for Catabasis Pharmaceuticals to $8 and removed CAT-2054 from his model after the agent failed to lower cholesterol on top of statins in a Phase 2 trial. The analyst, however, continues to see favorable risk/reward into Phase 2 data in late 2016 for lead agent CAT-1004 in Duchenne Muscular Dystrophy. Beatty keeps a Buy rating on Catabasis.

TODAY'S FREE FLY STORIES

NXTM

NxStage Medical

$23.46

0.13 (0.56%)

21:43
06/26/17
06/26
21:43
06/26/17
21:43
Initiation
NxStage Medical initiated at Craig-Hallum »

NxStage Medical initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

21:40
06/26/17
06/26
21:40
06/26/17
21:40
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

BL

BlackLine

$37.80

-0.26 (-0.68%)

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
BlackLine initiated at SunTrust »

BlackLine initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ULTI

Ultimate Software

$221.91

-0.25 (-0.11%)

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
Ultimate Software initiated at SunTrust »

Ultimate Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

CRM

Salesforce

$88.11

-0.51 (-0.58%)

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
Salesforce initiated at SunTrust »

Salesforce initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVBG

Everbridge

$24.66

-0.3 (-1.20%)

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
Everbridge initiated at SunTrust »

Everbridge initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNG

RingCentral

$37.65

-1 (-2.59%)

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
RingCentral initiated at SunTrust »

RingCentral initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WK

Workiva

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
Workiva initiated at SunTrust »

Workiva initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HUBS

HubSpot

$68.20

-0.7 (-1.02%)

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
HubSpot initiated at SunTrust »

HubSpot initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

HUBS

HubSpot

$68.20

-0.7 (-1.02%)

20:55
06/26/17
06/26
20:55
06/26/17
20:55
Initiation
HubSpot initiated at SunTrust »

HubSpot initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

QTWO

Q2 Holdings

20:55
06/26/17
06/26
20:55
06/26/17
20:55
Initiation
Q2 Holdings initiated at SunTrust »

Q2 Holdings initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

INST

Instructure

$29.55

0.4 (1.37%)

20:55
06/26/17
06/26
20:55
06/26/17
20:55
Initiation
Instructure initiated at SunTrust »

Instructure initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

MANH

Manhattan Associates

20:55
06/26/17
06/26
20:55
06/26/17
20:55
Initiation
Manhattan Associates initiated at SunTrust »

Manhattan Associates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCTY

Paylocity

$47.39

-1.65 (-3.36%)

20:55
06/26/17
06/26
20:55
06/26/17
20:55
Initiation
Paylocity initiated at SunTrust »

Paylocity initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

SHOP

Shopify

$92.04

-2.44 (-2.58%)

20:55
06/26/17
06/26
20:55
06/26/17
20:55
Initiation
Shopify initiated at SunTrust »

Shopify initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LH

LabCorp

$152.30

0.68 (0.45%)

20:10
06/26/17
06/26
20:10
06/26/17
20:10
Downgrade
LabCorp rating change at KeyBanc »

LabCorp downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATXI

Avenue Therapeutics

20:06
06/26/17
06/26
20:06
06/26/17
20:06
Syndicate
Avenue Therapeutics 5.5M share IPO priced at $6.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

NXPI

NXP Semiconductors

$109.73

-0.25 (-0.23%)

20:05
06/26/17
06/26
20:05
06/26/17
20:05
Hot Stocks
NXP Semi collaborates with Shanghai Unicom, roam2free on eSIM solution »

NXP Semiconductors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 26

    Jun

PDCE

PDC Energy

$42.88

-1.84 (-4.11%)

19:21
06/26/17
06/26
19:21
06/26/17
19:21
Hot Stocks
PDC Energy CEO 'disappointed' with Clean Air Act complaint »

Today, the U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

MRIN

Marin Software

$1.18

0.025 (2.17%)

19:17
06/26/17
06/26
19:17
06/26/17
19:17
Hot Stocks
Marin Software names Brad Kinnish CFO »

Marin Software announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$34.52

0.32 (0.94%)

19:15
06/26/17
06/26
19:15
06/26/17
19:15
Earnings
General Motors: Previous FY17 EPS view unchanged »

General Motors said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 25

    Jul

GM

General Motors

$34.52

0.32 (0.94%)

19:04
06/26/17
06/26
19:04
06/26/17
19:04
Hot Stocks
General Motors lowers view of 2017 U.S. car industry »

On a conference call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 25

    Jul

BLKB

Blackbaud

$89.25

-0.25 (-0.28%)

, CST

CST Brands

$48.54

0.18 (0.37%)

18:56
06/26/17
06/26
18:56
06/26/17
18:56
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P SmallCap 600…

BLKB

Blackbaud

$89.25

-0.25 (-0.28%)

CST

CST Brands

$48.54

0.18 (0.37%)

NSA

National Storage

$22.63

0.22 (0.98%)

ANCUF

Alimentation Couche-Tard

$48.08

1.9887 (4.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$34.52

0.32 (0.94%)

18:52
06/26/17
06/26
18:52
06/26/17
18:52
Hot Stocks
General Motors raises expected Opel sale charge to $5.5B »

On a conference call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 25

    Jul

WMT

Wal-Mart

$75.50

0.66 (0.88%)

18:43
06/26/17
06/26
18:43
06/26/17
18:43
Periodicals
Wal-Mart sued for wrongful death of Illinois Uber driver, Reuters reports »

The family of an Illinois…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.